Immusoft, a Propel(x) portfolio company, has received FDA Fast Track designation for its ISP-001 therapy. This designation highlights the potential of Immusoft’s engineered B-cell platform to address urgent unmet medical needs in rare diseases.
The FDA Fast Track designation marks a major milestone in Immusoft’s mission to transform treatment options for patients with serious genetic disorders.
Key Milestones from Immusoft
Over the past year, Immusoft has reached several important clinical and scientific milestones:
- Dosed the first patient with ISP-001 in early 2024, marking a first-in-human milestone for engineered B-cell therapy in Mucopolysaccharidosis Type I (MPS I)
- Reported positive Phase 1 data in 2024, demonstrating encouraging safety results and early signs of clinical benefit
- Presented research in 2025 at leading global forums, including WORLDSymposium™ 2025 and ASGCT 2025, reflecting growing recognition across the biotech community
These achievements demonstrate the Immusoft team’s scientific rigor, persistence, and long-term vision. We’re proud to support their journey alongside respected investors, including 8VC, Tao Capital Partners, TECHU, and Digitalis Ventures.
At Propel(x), we remain committed to backing founders who are translating innovative science into therapies that can change lives.
Stay on top of biotech breakthroughs and discover investment opportunities. Register at propelx.com
